Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)
- Conditions
- Diabetic Macular EdemaDiabetic Retinopathy
- Interventions
- Genetic: ADVM-022
- First Posted Date
- 2022-11-07
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Adverum Biotechnologies, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT05607810
- Locations
- 🇵🇷
Adverum Clinical Site, Arecibo, Puerto Rico
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]
Phase 2
Active, not recruiting
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Genetic: ADVM-022
- First Posted Date
- 2022-09-13
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Adverum Biotechnologies, Inc.
- Target Recruit Count
- 69
- Registration Number
- NCT05536973
- Locations
- 🇺🇸
Adverum Clinical Site 162, McAllen, Texas, United States
🇺🇸Adverum Clinical Site 108, Bellaire, Texas, United States
🇬🇧Adverum Clinical Site 601, Oxford, United Kingdom
Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]
Active, not recruiting
- Conditions
- Wet Age-related Macular DegenerationNeovascular Age-related Macular Degeneration
- Interventions
- Biological: ADVM-022
- First Posted Date
- 2020-11-27
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Adverum Biotechnologies, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT04645212
- Locations
- 🇺🇸
Adverum Clinical Site, The Woodlands, Texas, United States
ADVM-022 Intravitreal Gene Therapy for DME
Phase 2
Completed
- Conditions
- Diabetic Macular EdemaDiabetic Retinopathy
- Interventions
- Biological: AfliberceptBiological: 6E11 vg/eye of ADVM-022Biological: 2E11 vg/eye of ADVM-022
- First Posted Date
- 2020-06-05
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- Adverum Biotechnologies, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT04418427
- Locations
- 🇵🇷
Adverum Clinical Site, Arecibo, Puerto Rico
Long-Term Follow-up Study of ADVM-043
Completed
- Conditions
- Alpha-1 Antitrypsin Deficiency
- Interventions
- Genetic: No Intervention
- First Posted Date
- 2019-01-15
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Adverum Biotechnologies, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT03804021
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
🇺🇸Medical University of South Carolina, Charleston, South Carolina, United States
ADVM-022 Intravitreal Gene Therapy for Wet AMD
Phase 1
Completed
- Conditions
- Wet Age-related Macular DegenerationNeovascular Age-related Macular Degeneration
- Interventions
- Biological: ADVM-022
- First Posted Date
- 2018-11-21
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- Adverum Biotechnologies, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT03748784
- Locations
- 🇺🇸
Adverum Clinical Site, The Woodlands, Texas, United States
A Study to Characterize the Cardiac Phenotype of Individuals With Friedreich's Ataxia (CARFA Study)
Not Applicable
Completed
- Conditions
- Friedreich's Ataxia
- Interventions
- Procedure: Cardiac magnetic resonance imaging (CMR)Procedure: Exercise-stress testProcedure: Echocardiography (ECHO)Procedure: Cardiac-related blood studies
- First Posted Date
- 2016-07-21
- Last Posted Date
- 2018-12-10
- Lead Sponsor
- Adverum Biotechnologies, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT02840669
- Locations
- 🇫🇷
Hôpital Pitié-Salpêtrière, AP-HP, Paris, France
Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency
Phase 1
Completed
- Conditions
- Alpha 1-Antitrypsin Deficiency
- Interventions
- Genetic: ADVM-043
- First Posted Date
- 2014-06-20
- Last Posted Date
- 2023-10-05
- Lead Sponsor
- Adverum Biotechnologies, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT02168686
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸University of Florida, Gainesville, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath